About
Resources
Blog
CDC Data
Infographics
Social Media Graphics
Papers
Podcasts
Videos
Webinars
Disease State
AFib
Heart Failure
High Cholesterol
Hypertension
Hypertrophic Cardiomyopathy
Obesity
Peripheral Artery Disease
Advocacy
ICER
MINI Act
No Big Deal
PCSK9 Rejections
Take Action
CLA
Contact
Subscribe
Contact PACH
Membership
Upcoming Events

Partnership to Advance Cardiovascular Health

About
Resources
Blog
CDC Data
Infographics
Social Media Graphics
Papers
Podcasts
Videos
Webinars
Disease State
AFib
Heart Failure
High Cholesterol
Hypertension
Hypertrophic Cardiomyopathy
Obesity
Peripheral Artery Disease
Advocacy
ICER
MINI Act
No Big Deal
PCSK9 Rejections
Take Action
CLA
Contact
Subscribe
Contact PACH
Membership
Upcoming Events
What Price Reductions for Cholesterol-lowering Medications Mean for Patients
October 26, 2018
AfPA Digital
What Price Reductions for Cholesterol-lowering Medications Mean for Patients
AfPA Digital
October 26, 2018

What Price Reductions for Cholesterol-lowering Medications Mean for Patients

AfPA Digital
October 26, 2018

Patient advocates across the country cheered this week as news spread about a decrease in the list price of evolocumab.  The medication is a PCSK9 inhibitor – a “cholesterol buster” that can lower high LDL cholesterol when traditional statins alone are not effective.

Read more.

Newer PostDo prescription drug middlemen help keep prices high?
Older PostPoll: Health Plan Delays are “Unreasonable,” Dangerous for Heart Patients
Back to Top

Partnership to Advance Cardiovascular Health